《盈利預喜》健倍苗苗(02161.HK)料中期綜合溢利按年增長3倍
健倍苗苗(02161.HK)發盈喜,預期截至今年9月底止中期綜合溢利將達約6,200萬元,約為去年同期的3倍。
公司指出,綜合溢利大幅增加主要歸因於入境旅遊業復甦帶動正面的市場氣氛。公司持續有效執行品牌管理及銷售策略,明顯提升各產品分部(尤其是品牌藥)的銷售收益增加以及銷售利潤率上升。此優異表現突顯公司對戰略重點的審慎部署,以及有效的營運能力。
此外,公司相信香港經濟及入境旅遊持續復甦將繼續令零售行業受惠,而費者對健康管理的重視,以及網上購物的發展趨勢,將繼續推動消費者保健市場的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.